Endocrine Therapy Drugs (ETDs) Market: The increasing incidence of chronic diseases such as breast cancer, diabetes, and others is expected to drive the growth of the market | Novo Nordisk A/S, AstraZeneca, Generex Biotechnology

Overview:

The endocrine system in humans acts like a messenger system which consists of several chemical messengers which are released by the endocrine glands. These are released in the blood and then sent to target organs.  These chemical messengers are known as hormones. Blocking and removing hormones for treating several diseases like diabetes, postmenopausal symptoms and breast cancer, is known as Endocrine therapy or it is also called as hormone therapy. Endocrine therapy has an agent which targets the hormone which is the cause of a disease or it targets the organ which is secreting that hormone.

Global Endocrine Therapy Drugs (ETDs) Market is anticipated to be valued at US$ 28,958.4 Mn in 2022, over the forecast period.

To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5193

Impact of COVID-19:

COVID-19 was first reported in 2019 in China. The Weekly Epidemiological Update by the WHO mentioned that until February 6, 2022, more than 392 million cases of COVID-19 were reported and almost 4.7 million fatalities had occurred due to COVID-19 around the world.

The pandemic affected various markets around the world. Moreover, it is estimated that the pandemic had a positive impact on the global endocrine therapy drugs (ETDs) market, due to increasing research and developmental activities being conducted for determining the role of hormones in preventing COVID-19. For instance, the Cancers journal published an article in August 2020, stating that high levels of testosterone can regulate transmembrane serine protease 2, which is a cell receptor that is involved in the entry of the COVID-19 virus. Ongoing studies are determining the role of enzalutamide and bicalutamide in providing immunity from the coronavirus in cancer patients.

Drivers:

Major players are focusing on gaining approvals from regulatory authorities, which is estimated to propel growth of the global endocrine therapy drugs (ETDS) market over the forecast period. For instance, Novartis AG gained approval for their Kisqali, an endocrine therapy drug along with an aromatase inhibitor, this is used for treating pre/post-menopausal women suffering from breast cancer.

Inquire More Or Share Questions If Any Before The Purchase On This Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/5193

Increasing adoption of growth strategies like acquisitions and collaborations for strengthening their position in the global endocrine therapy drugs (ETDS) market over the forecast period. For instance, Myovant Sciences GmbH and Pfizer Inc., declared their collaboration for developing and commercializing ORGOVYX, in April 2021. This is used in endocrine therapy while treating endometriosis and uterine fibroids in women and prostate cancer in men.

Key Takeaways:

• The global endocrine therapy drugs (ETDs) market is estimated to exhibit a CAGR of 5.1% during the forecast period, due to increasing gained approval from regulatory approvals for endocrine therapy drugs. For instance, AstraZeneca, gained approval from the U.S. Food and Drugs Administration, for Faslodex, their endocrine therapy drug for post post-menopausal women suffering from breast cancer.
• Breast cancer segment, among application in the global endocrine therapy drugs (ETDs) market is estimated to witness significant growth over the forecast period, due to increasing prevalence and growing incidences of breast cancer. For instance, the American Cancer Society Facts and Figures 2022, estimated that in the U.S. women accounted for almost 287,850 breast cancer cases and men reported 2,710 cases of breast cancer in 2020

Key players:

Major players active in the global endocrine therapy drugs (ETDs) market are QuatRx Pharmaceuticals, Novo Nordisk A/S, Noven Pharmaceuticals, Inc., AstraZeneca, Amgen Inc., Generex Biotechnology, BioSante Pharmaceuticals, Orion Pharma AB, Allergan, Orion Pharma AB, Pfizer Inc., Sanofi, TherapeuticsMD, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., F. Hoffmann-La Roche, Tonghua Dongbao Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co.,Inc., Abbott, Bayer AG and Eli Lilly and Company.

Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/5193

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Type
     • Market Snippet, By Application
     • Market Snippet, By Distribution Channel
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Pipeline Analysis
   • PEST Analysis
   • Regulatory Scenario
   • Market Trends
   • Key Highlights
   • Reimbursement Scenario
   • Mergers & Acquisitions
   • Epidemiology
4. Global Endocrine Therapy Drugs (ETDs) Market – Impact of Coronavirus (Covid-19) Pandemic
   • Economic Impact
   • Impact on Clinical Trials and Drug Development
   • Government Initiatives
5. Global Endocrine Therapy Drugs (ETDs) Market, By Drug Type, 2017 – 2030, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Anti-diabetic Drugs
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Anti-osteoporosis Drugs
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Contraceptive Drugs
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Breast Cancer Drugs
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Others (Menopause Drugs, among others)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
6. Global Endocrine Therapy Drugs (ETDs) Market, By Application, 2017 – 2030, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Diabetes
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Breast Cancer
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Osteoporosis
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Menopause
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Contraception
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Others (Gender Reassignment Surgery, Hypothyroidism, among others)
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
7. Global Endocrine Therapy Drugs (ETDs) Market, By Distribution Channel, 2017 – 2030, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Hospital Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Retail Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
   • Online Pharmacies
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)

View Press Release: https://www.coherentmarketinsights.com/press-release/endocrine-therapy-drugs-market-4483